Antiandrogen Therapy

DRUG20 trials

Sponsors

Burzynski Research Institute, UNICANCER, Peter MacCallum Cancer Centre, Australia, OHSU Knight Cancer Institute, University of Washington

Conditions

Adenocarcinoma of the ProstateBiochemically Recurrent Prostate CarcinomaCastration-Sensitive Prostate CarcinomaMetastatic CancerMetastatic Malignant Neoplasm in Lymph NodeMetastatic Malignant Neoplasm in the BoneMetastatic Prostate CarcinomaMetastatic Prostatic Adenocarcinoma

Phase 1

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

CompletedNCT02472275

Barbara Ann Karmanos Cancer InstituteStage III Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma

Start: 2015-06-30End: 2019-08-05Updated: 2020-10-06

Phase 2

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

WithdrawnNCT00003517

Burzynski Research InstituteAdenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage III Prostate Cancer +1

Updated: 2013-07-10

Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer

WithdrawnNCT00244920

OHSU Knight Cancer InstituteProstate Cancer

Start: 2002-01-31End: 2007-06-30Updated: 2012-05-28

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

CompletedNCT01409200

M.D. Anderson Cancer CenterMetastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7 +1

Start: 2012-03-26End: 2026-02-05Updated: 2026-03-03

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Active, not recruitingNCT03456843

Yale UniversityStage IV Prostate Adenocarcinoma AJCC v7

Start: 2018-03-20End: 2027-03-01Target: 190Updated: 2026-01-21

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Active, not recruitingNCT03541850

Jonsson Comprehensive Cancer CenterPSA Level Greater Than 0.03, PSA Progression, Stage III Prostate Adenocarcinoma AJCC v7 +2

Start: 2019-01-29End: 2027-11-01Updated: 2025-11-06

Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer

TerminatedNCT03649841

University of WashingtonCastration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma +5

Start: 2020-06-29End: 2023-02-01Updated: 2023-10-26

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

TerminatedNCT03827473

University of UtahCastration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IVA Prostate Cancer +2

Start: 2019-02-08End: 2019-07-31Updated: 2020-06-25

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Active, not recruitingNCT04267887

OHSU Knight Cancer InstituteCastration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2020-05-11End: 2030-01-01Updated: 2026-01-20

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

RecruitingNCT04947254

M.D. Anderson Cancer CenterProstate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8 +4

Start: 2021-08-05End: 2026-06-07Target: 200Updated: 2026-02-19

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

TerminatedNCT05676463

Thomas Jefferson UniversityProstate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8

Start: 2022-11-16End: 2025-10-24Updated: 2026-03-03

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial

RecruitingNCT06244004

Northwestern UniversityCastration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2024-02-18End: 2028-02-18Target: 125Updated: 2026-03-30

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

RecruitingNCT07202247

City of Hope Medical CenterProstate Carcinoma, Recurrent Prostate Carcinoma

Start: 2026-01-23End: 2028-04-09Target: 60Updated: 2026-02-04

Phase 3

Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer

CompletedNCT00104715

UNICANCERProstate Cancer

Start: 2004-10-18End: 2015-12-15Updated: 2021-02-21

Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

Peter MacCallum Cancer Centre, AustraliaProstate Cancer

Start: 2004-10-31Target: 2000Updated: 2013-08-07

Androgen Blockade Therapy With or Without Zoledronic Acid in Treating Patients With Prostate Cancer and Bone Metastases

CompletedNCT00685646

Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanMetastatic Cancer, Prostate Cancer

Start: 2008-05-31End: 2014-01-31Updated: 2015-10-16

Post-operative or Early Salvage XRT and ADT for High Risk PCa

TerminatedNCT00949962

European Organisation for Research and Treatment of Cancer - EORTCProstate Cancer

Start: 2009-10-31End: 2016-06-30Updated: 2014-07-04

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

RecruitingNCT06205316

Mayo ClinicBiochemically Recurrent Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Recurrent Prostate Adenocarcinoma +4

Start: 2024-01-22End: 2030-01-22Target: 118Updated: 2026-01-20

Unknown Phase

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

CompletedNCT00392938

University of WashingtonMetastatic Cancer, Prostate Cancer

Start: 2005-12-31Updated: 2017-03-13

Study of Blood and Tissue Samples From Patients Receiving Androgen Deprivation for Newly Diagnosed Prostate Cancer

Cancer Research UKProstate Cancer

Start: 2008-09-30Target: 120Updated: 2014-01-10

Related Papers

Patient-Reported Outcomes With Stereotactic Intensity Modulated Radiotherapy After Radical Prostatectomy: A Nonrandomized Clinical Trial.

2025-07-015 citations

Stereotactic intensity modulated radiotherapy after radical prostatectomy (SCIMITAR): Two-year quality of life and toxicity outcomes of a multicenter phase II trial.

Journal of Clinical Oncology2024-01-291 citations

Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2023-06-018 citations

The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2023-06-012 citations

PD15-08 PROSTATE BED DEFORMATIONS AND DOSIMETRIC IMPLICATIONS: AN EXPLORATORY ANALYSIS OF A PHASE II CLINICAL TRIAL (SCIMITAR)

The Journal of Urology2023-03-23

Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.

Journal of Clinical Oncology2019-05-202 citations

Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.

Journal of Clinical Oncology2018-05-2011 citations

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

2017-07-2843 citations

Burden of metastatic hormone-sensitive prostate cancer to identify men more likely to benefit from early docetaxel.

Journal of Clinical Oncology2017-02-206 citations

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

2016-05-04160 citations

A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naïve prostate cancer patients with bone metastases: Results of ZAPCA study.

Journal of Clinical Oncology2015-03-014 citations

Improving the pre-screening of eligible patients in order to increase enrollment in cancer clinical trials

Trials2015-01-1523 citations

Presurgical axitinib and androgen deprivation therapy (ADT) in prostate cancer (PCa) patients (pts) presenting with lymph node (LN) metastasis.

Journal of Clinical Oncology2014-05-20

Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].

2013-11-013 citations

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

2013-01-08501 citations